Genovis and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody conjugation technology
Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT Therapeutics (“GlycoT”) to market, sell and further develop enzymatic workflows for the research and diagnostics markets as well as for therapeutic applications.As part of the cross-licensing agreements, Genovis will license enzyme technology from GlycoT and at the same time out-license enzyme technology to GlycoT. The exchange of technology access enables both companies to offer a significantly improved enzyme driven workflow technology to increase the implementation of site-specific antibody